The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.

ABSTRACT:

Background

Recent evidence suggested a potential correlation between BMI and the efficacy of immune checkpoint inhibitors in cancer patients. This study aimed to evaluate the prognostic value of the body mass index (BMI) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treat with pembrolizumab.

Methods

The current retrospective cohort study enrolled 49 R/M HNSCC patients underwent at least one cycle of pembrolizumab as second-line treatment from June 2018 to October 2020. Survival analysis of immunotherapy prognosis and risk factor analysis of age, gender, BMI, ECOG-PS, CPS, rT-stage, tumor site, and tube feeding.

Results

Among the 49 patients, the BMI at the time of immunotherapy ranged from 14.5 to 32.0 kg/m² . The Kaplan

SUBMITTER: Zhang X 

PROVIDER: S-EPMC9939135 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature